Evidence map›Paper›PMID 29388577›Full record

ReviewPediatric health, medicine and therapeutics2015

Profile of infliximab in the treatment of pediatric Crohn's disease.

Jaroslaw Kierkus, Edyta Szymanska, Grzegorz Oracz, Anna Wiernicka, Maciej Dadalski

Open access · goldAbstract readReview
In one paragraph

Review in Pediatric health, medicine and therapeutics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Jaroslaw KierkusDepartment of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics.
Edyta SzymanskaDepartment of Pediatrics, Nutrition and Metabolic Disorders, The Children's Memorial Health Institute, Warsaw, Poland.
Grzegorz OraczDepartment of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics.
Anna WiernickaDepartment of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics.
Maciej DadalskiDepartment of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics.
Feed Control (Norway) · NOChildren's Memorial Health Institute · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, a novel biologic therapy with monoclonal antibodies against tumor necrosis factor-alpha has revolutionized the treatment of Crohn's disease. Infliximab, the first biologic agent, has been demonstrated to considerably improve both clinical and endoscopic outcomes. In view of the growing popularity of infliximab in the management of Crohn's disease, we review the profile of the agent in the treatment of this disease in a pediatric setting.

Indexed as

anti-TNF-agentsbiologic therapychildrenCrohn’s diseaseinfliximab

Identifiers

PMID29388577
PMCPMC5683274
OpenAlexW1770921651

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.